Araris Biotech completes CHF15.2m seed financing round
Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, has received an additional CHF12.7 million in seed financing, bringing the total amount raised to CHF15.2 million.The investment round was led by Pureos Bioventures with participation from new investors 4BIO Capital, btov Partners and existing investors Redalpine, VI Partners and
